tiprankstipranks
Nurexone Biologic Inc. (TSE:NRX)
:NRX
Canadian Market

NurExone Biologic (NRX) Income Statement

Compare
3 Followers

NurExone Biologic Income Statement

Last quarter (Q3 2024), NurExone Biologic's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, NurExone Biologic's net income was $-3.50M. See NurExone Biologic’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ 17.66B$ 20.85B$ 13.61B$ 6.63B$ 4.07B
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 3.33B$ 60.61B$ ―$ 1.57B$ 1.37B
EBITDA
$ 14.80B$ 17.66B$ 9.64B$ 4.30B$ 2.43B
Operating Income
$ 8.89B$ 13.66B$ 6.52B$ 1.99B$ -69.00M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ 15.00B$ 12.56B$ 5.52B$ 721.00M$ -862.00M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

NurExone Biologic Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis